FindTrial
Sign In

Femara 2

DRUG2 trials

Sponsors

Region Oerebro Laen, Solti Group

Conditions

Advanced Breast Cancer in older patientsHR+/HER2breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole.Ki67 #20%Patients with primary operable stage IIgrade 2 or 3

Phase 2

Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS)
Active, not recruitingCTIS2023-508827-10-00
Solti Groupgrade 2 or 3, HR+/HER2breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole., Ki67 #20% +1
Start: 2025-10-13Target: 1100Updated: 2026-01-07

Phase 3

IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial)
RecruitingCTIS2023-506620-87-00
Region Oerebro LaenAdvanced Breast Cancer in older patients
Start: 2024-01-25Target: 495Updated: 2025-07-10